AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22164329 — intervention group
Group type: COMPARATOR
Intervention: Health Education Control (HEC)
Number of subjects: 162
Study 22164329 — intervention group
Group type: COMPARATOR
Intervention: Life Skills Training (LST)
Number of subjects: 162
Study 20692567 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspheric Tecnis intraocular lens (IOL)
Number of subjects: 28
Study 20692567 — intervention group
Group type: COMPARATOR
Intervention: Sensar AR40e spherical IOL
Number of subjects: 28
Study 18793562 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training during hemodialysis (Group A)
Number of subjects: 43
Study 18793562 — intervention group
Group type: COMPARATOR
Intervention: Sedentary control group (Group B)
Number of subjects: 43
Study 18793562 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group (Group C)
Number of subjects: 43
Study 15733875 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral misoprostol 50 mug orally every 4 h
Number of subjects: 200
Study 15733875 — intervention group
Group type: COMPARATOR
Intervention: Intracervical dinoprostone 0.5 mg every 6 h
Number of subjects: 200
Study 15733875 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal and neonatal outcomes
Number of subjects: 200
Study 12938066 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg of amitriptyline
Number of subjects: 60
Study 12938066 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg of mirtazapine
Number of subjects: 60
Study 11069330 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 0
Study 11069330 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 0
Study 11069330 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 0
Study 11069330 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (Isoflurane, Sevoflurane, Desflurane)
Number of subjects: 0
Study 8676277 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioresorbable matrix barrier (test)
Number of subjects: 12
Study 8676277 — intervention group
Group type: COMPARATOR
Intervention: Non-resorbable expanded polytetrafluoroethylene membrane (control)
Number of subjects: 12
Study 31570179 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg L-DOPA
Number of subjects: 52
Study 31570179 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg L-DOPA
Number of subjects: 52
Study 31570179 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 30562352 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency messaging (HFM)
Number of subjects: 1369
Study 30562352 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency messaging (LFM)
Number of subjects: 1369
Study 30562352 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1369
Study 27344610 — intervention group
Group type: EXPERIMENTAL
Intervention: Thin dolls (Barbie™) dressed in a swimsuit
Number of subjects: 112
Study 27344610 — intervention group
Group type: EXPERIMENTAL
Intervention: Thin dolls (Barbie™) dressed in modest clothing
Number of subjects: 112
Study 27344610 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-figured dolls (Tracy™) dressed in a swimsuit
Number of subjects: 112
Study 27344610 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-figured dolls (Tracy™) dressed in modest clothing
Number of subjects: 112
Study 27344610 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfamiliar thin dolls dressed in a swimsuit
Number of subjects: 112
Study 27344610 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfamiliar thin dolls dressed in modest clothing
Number of subjects: 112
Study 27344610 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfamiliar full-figured dolls dressed in a swimsuit
Number of subjects: 112
Study 27344610 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfamiliar full-figured dolls dressed in modest clothing
Number of subjects: 112
Study 24630611 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with NF1
Number of subjects: 0
Study 24630611 — intervention group
Group type: COMPARATOR
Intervention: Control group (typical development)
Number of subjects: 0
Study 22677735 — intervention group
Group type: EXPERIMENTAL
Intervention: Video eyewear with nitrous oxide/oxygen sedation (group NE)
Number of subjects: 38
Study 22677735 — intervention group
Group type: COMPARATOR
Intervention: No video eyewear with nitrous oxide/oxygen sedation (group N)
Number of subjects: 38
Study 18450126 — intervention group
Group type: EXPERIMENTAL
Intervention: Echinacea (3 capsules twice daily for 8 weeks)
Number of subjects: 90
Study 18450126 — intervention group
Group type: COMPARATOR
Intervention: Placebo (parsley, 3 capsules twice daily for 8 weeks)
Number of subjects: 90
Study 18450126 — intervention group
Group type: EXPERIMENTAL
Intervention: Echinacea
Number of subjects: 90
Study 18450126 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 16621618 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous methyl prednisolone for 5 days along with antiepileptic drug
Number of subjects: 52
Study 16621618 — intervention group
Group type: COMPARATOR
Intervention: Antiepileptic drug monotherapy
Number of subjects: 52
Study 14615654 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa 40,000 to 60,000 U once weekly (QW)
Number of subjects: 285
Study 14615654 — intervention group
Group type: COMPARATOR
Intervention: Epoetin alfa 100 to 300 U/kg three times weekly (TIW)
Number of subjects: 285
Study 11063978 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 0
Study 9157582 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined prescription and monitoring charts for heparin
Number of subjects: 700
Study 9157582 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined prescription and monitoring charts for warfarin
Number of subjects: 700
Study 9157582 — intervention group
Group type: COMPARATOR
Intervention: Control (no charts)
Number of subjects: 700
Study 1286541 — intervention group
Group type: EXPERIMENTAL
Intervention: Long acting crystalline zinc insulin
Number of subjects: 0
Study 1286541 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide
Number of subjects: 0
Study 1286541 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 0
Study 1286541 — intervention group
Group type: COMPARATOR
Intervention: Control group (baseline measurements)
Number of subjects: 0
Study 29552775 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Recovery After Surgery (ERAS)
Number of subjects: 114
Study 29552775 — intervention group
Group type: COMPARATOR
Intervention: Conventional management procedures (Regular group)
Number of subjects: 114
Study 27281638 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based worksite intervention (eight-week mindfulness training, e-coaching, and supporting elements)
Number of subjects: 257
Study 27281638 — intervention group
Group type: COMPARATOR
Intervention: Usual practice (control group)
Number of subjects: 257
Study 27281638 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based worksite intervention
Number of subjects: 257
Study 23940000 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical atorvastatin 1% ointment applied once/day for 14 days
Number of subjects: 104
Study 22341565 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training
Number of subjects: 72
Study 22341565 — intervention group
Group type: COMPARATOR
Intervention: Aerobic exercise
Number of subjects: 72
Study 20038732 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitoxantrone/cytarabine/etoposide
Number of subjects: 1658
Study 20038732 — intervention group
Group type: COMPARATOR
Intervention: Cytarabine/daunorubicin/etoposide
Number of subjects: 1658
Study 20038732 — intervention group
Group type: EXPERIMENTAL
Intervention: Daunorubicin/cytarabine/thioguanine (S-DAT)
Number of subjects: 1658
Study 20038732 — intervention group
Group type: EXPERIMENTAL
Intervention: Daunorubicin/cytarabine/thioguanine (H-DAT)
Number of subjects: 1658
Study 20038732 — intervention group
Group type: EXPERIMENTAL
Intervention: Four courses of chemotherapy
Number of subjects: 1658
Study 20038732 — intervention group
Group type: EXPERIMENTAL
Intervention: Transplantation as final course
Number of subjects: 1658
Study 20038732 — intervention group
Group type: EXPERIMENTAL
Intervention: Five courses of chemotherapy
Number of subjects: 1658
Study 18537469 — intervention group
Group type: EXPERIMENTAL
Intervention: Japanese acupuncture (JA)
Number of subjects: 0
Study 18537469 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture using the Streitberger device and sham moxibustion
Number of subjects: 0
Study 16609319 — intervention group
Group type: EXPERIMENTAL
Intervention: Network-based geriatric rehabilitation programme
Number of subjects: 741
Study 16609319 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 741
Study 14638354 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa (40,000 units, s.c. once weekly)
Number of subjects: 64
Study 14638354 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC) for anemia management (RBV dose reduction or discontinuation, transfusions)
Number of subjects: 64
Study 10972451 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment (CBT) for panic disorder, 12 hours in addition to regular alcoholism treatment program.
Number of subjects: 0
Study 10972451 — intervention group
Group type: COMPARATOR
Intervention: Regular alcoholism treatment program (Control group).
Number of subjects: 0
Study 8855742 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic variceal ligation (EVL)
Number of subjects: 44
Study 8855742 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic injection sclerotherapy (EIS)
Number of subjects: 44
Study 1738796 — intervention group
Group type: EXPERIMENTAL
Intervention: Physostigmine (0.75 mg SC)
Number of subjects: 10
Study 1738796 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyoscine (1.2 mg)
Number of subjects: 10
Study 1738796 — intervention group
Group type: EXPERIMENTAL
Intervention: Temazepam (20 mg)
Number of subjects: 10
Study 1738796 — intervention group
Group type: EXPERIMENTAL
Intervention: Flecainide (200 mg)
Number of subjects: 10
Study 1738796 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 6380695 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole
Number of subjects: 140
Study 6380695 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study 29402358 — intervention group
Group type: EXPERIMENTAL
Intervention: Early mobilization (joint activity, standing to the bed, 3 times a day)
Number of subjects: 60
Study 29402358 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard treatment without early mobilization)
Number of subjects: 60
Study 27332197 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal Health Network (PHN)
Number of subjects: 12
Study 24701731 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh gas flow (FGF) rate at 0.5 L x min(‐1)
Number of subjects: 30
Study 24701731 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh gas flow (FGF) rate at 1 L x min(‐1)
Number of subjects: 30
Study 24701731 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh gas flow (FGF) rate at 2 L x min(‐1)
Number of subjects: 30
Study 22108830 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate invasive approach (<2 h after randomization)
Number of subjects: 602
Study 22108830 — intervention group
Group type: COMPARATOR
Intervention: Early invasive approach (10-48 h after randomization)
Number of subjects: 602
Study 22108830 — intervention group
Group type: COMPARATOR
Intervention: Selective invasive approach (high invasive percentage, >48 h after randomization)
Number of subjects: 602
Study 22108830 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate invasive approach
Number of subjects: 602
Study 22108830 — intervention group
Group type: COMPARATOR
Intervention: Early invasive approach
Number of subjects: 602
Study 22108830 — intervention group
Group type: COMPARATOR
Intervention: Selective invasive approach
Number of subjects: 602
Study 20829701 — intervention group
Group type: EXPERIMENTAL
Intervention: TruView EVO2 laryngoscope (Group T, n = 25)
Number of subjects: 50
Study 20829701 — intervention group
Group type: COMPARATOR
Intervention: Miller laryngoscope (Group M, n = 25)
Number of subjects: 50
Study 18325863 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunonutrition (enteral nutrition supplemented with glutamine, arginine, and/or omega-3 fatty acids)
Number of subjects: 3
Study 16878408 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical resection
Number of subjects: 0
Study 16878408 — intervention group
Group type: COMPARATOR
Intervention: Chemo-radiation therapy
Number of subjects: 0
Study 12749498 — intervention group
Group type: EXPERIMENTAL
Intervention: Permethrin-treated bed nets (ITNs)
Number of subjects: 0
Study 12749498 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study 12749498 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention homes
Number of subjects: 0
Study 12749498 — intervention group
Group type: EXPERIMENTAL
Intervention: Willingness to pay for bed nets
Number of subjects: 0
Study 8822163 — intervention group
Group type: EXPERIMENTAL
Intervention: Relational processing tasks (category sorting)
Number of subjects: 0
Study 8822163 — intervention group
Group type: EXPERIMENTAL
Intervention: Relational processing tasks (narrative construction)
Number of subjects: 0
Study 8822163 — intervention group
Group type: EXPERIMENTAL
Intervention: Relational processing tasks (relational imagery)
Number of subjects: 0
Study 8822163 — intervention group
Group type: EXPERIMENTAL
Intervention: Item-specific processing tasks (pleasantness ratings)
Number of subjects: 0
Study 8822163 — intervention group
Group type: EXPERIMENTAL
Intervention: Item-specific processing tasks (familiarity ratings)
Number of subjects: 0
Study 8822163 — intervention group
Group type: EXPERIMENTAL
Intervention: Item-specific processing tasks (single imagery)
Number of subjects: 0
Study 1359978 — intervention group
Group type: EXPERIMENTAL
Intervention: metipranolol 0.3%
Number of subjects: 7
Study 1359978 — intervention group
Group type: COMPARATOR
Intervention: timolol maleate 0.5%
Number of subjects: 7
Study 3926729 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin infusion added to parenteral feed
Number of subjects: 6
Study 3926729 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin infusion
Number of subjects: 6
Study 3926729 — intervention group
Group type: COMPARATOR
Intervention: Without insulin
Number of subjects: 6
Study 31395104 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral decompression via unilateral laminotomy (BDUL)
Number of subjects: 50
Study 31395104 — intervention group
Group type: COMPARATOR
Intervention: Conventional laminectomy (CL)
Number of subjects: 50
Study 30640244 — intervention group
Group type: EXPERIMENTAL
Intervention: Local infiltration analgesia (LIA) with bupivacaine and levobupivacaine 2 mg/kg and adrenaline 0.5 mg
Number of subjects: 43
Study 30640244 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal morphine 0.3 mg
Number of subjects: 43
Study 27992826 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief cognitive intervention
Number of subjects: 47
Study 27992826 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 47
Study 26011733 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose praziquantel (40 mg/kg body weight)
Number of subjects: 1017
Study 26011733 — intervention group
Group type: EXPERIMENTAL
Intervention: Double dose praziquantel (40 mg/kg body weight, second dose 2 weeks later)
Number of subjects: 1017
Study 26011733 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment regimens
Number of subjects: 1017
Study 23616162 — intervention group
Group type: EXPERIMENTAL
Intervention: 8OHdG levels measured by LCMS assay
Number of subjects: 160
Study 23616162 — intervention group
Group type: EXPERIMENTAL
Intervention: 8OHdG levels measured by LCECA assay
Number of subjects: 160
Study 23616162 — intervention group
Group type: EXPERIMENTAL
Intervention: 8OHdG levels measured by LCMS and LCECA assays
Number of subjects: 160
Study 21599990 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based dietary intervention for 6 months in addition to standard diabetes care
Number of subjects: 82
Study 21599990 — intervention group
Group type: COMPARATOR
Intervention: Standard diabetes care
Number of subjects: 82
Study 19029226 — intervention group
Group type: EXPERIMENTAL
Intervention: r-metHuLeptin treatment
Number of subjects: 118
Study 19029226 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study 16738291 — intervention group
Group type: EXPERIMENTAL
Intervention: 18G Special Sprotte needle
Number of subjects: 1077
Study 16738291 — intervention group
Group type: COMPARATOR
Intervention: 17G Tuohy needle
Number of subjects: 1077
Study 15326246 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training of elbow flexors and ankle dorsiflexors
Number of subjects: 65
Study 15326246 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol (sustained-release, 8 mg BID)
Number of subjects: 65
Study 15326246 — intervention group
Group type: COMPARATOR
Intervention: Non-training (placebo)
Number of subjects: 65
Study 11765072 — intervention group
Group type: EXPERIMENTAL
Intervention: BeamCath technique (76 Gy)
Number of subjects: 267
Study 11765072 — intervention group
Group type: COMPARATOR
Intervention: Conventional techniques (placebo)
Number of subjects: 267
Study 9401646 — intervention group
Group type: EXPERIMENTAL
Intervention: Exogenous GLP-1 [7-36 amide] infusion (0.4, 0.8 pmol kg-1 min-1)
Number of subjects: 9
Study 9401646 — intervention group
Group type: COMPARATOR
Intervention: Liquid mixed meal (50 g sucrose in 400 ml 8% amino acid)
Number of subjects: 9
Study 9401646 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control for GLP-1 infusion)
Number of subjects: 9
Study 8221563 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF (5.5 micrograms/kg protein dosage per day from day-6 to day-4 before chemotherapy)
Number of subjects: 12
Study 8221563 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy only (without GM-CSF)
Number of subjects: 12
Study 3304564 — intervention group
Group type: EXPERIMENTAL
Intervention: Methohexital (0.1 mg/kg/min continuous infusion)
Number of subjects: 60
Study 3304564 — intervention group
Group type: COMPARATOR
Intervention: Thiopental (5 mg/kg I.V. bolus)
Number of subjects: 60
Study 29055710 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC)
Number of subjects: 436
Study 29055710 — intervention group
Group type: COMPARATOR
Intervention: Control (sham intervention)
Number of subjects: 436
Study 27927175 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT) intervention
Number of subjects: 30
Study 27927175 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 30
Study 24901077 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow elastic cuffs
Number of subjects: 16
Study 24901077 — intervention group
Group type: COMPARATOR
Intervention: Narrow nylon cuffs
Number of subjects: 16
Study 23122924 — intervention group
Group type: EXPERIMENTAL
Intervention: Plastibell (PD)
Number of subjects: 198
Study 23122924 — intervention group
Group type: COMPARATOR
Intervention: Conventional dissection (CDS)
Number of subjects: 198
Study 20118151 — intervention group
Group type: EXPERIMENTAL
Intervention: Vascular closure device (VCD)
Number of subjects: 11621
Study 20118151 — intervention group
Group type: COMPARATOR
Intervention: No vascular closure device (No VCD)
Number of subjects: 11621
Study 20118151 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin monotherapy with VCD
Number of subjects: 11621
Study 20118151 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin monotherapy
Number of subjects: 11621
Study 20118151 — intervention group
Group type: EXPERIMENTAL
Intervention: VCD
Number of subjects: 11621
Study 18298700 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate 50 mg/day
Number of subjects: 1580
Study 18298700 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate 100 mg/day
Number of subjects: 1580
Study 18298700 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate 200 mg/day
Number of subjects: 1580
Study 18298700 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1580
Study 18298700 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (all doses combined)
Number of subjects: 1580
Study 16850316 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow walk (4.0 km h(‐1))
Number of subjects: 295
Study 16850316 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast walk (5.6 km h(‐1))
Number of subjects: 295
Study 16850316 — intervention group
Group type: EXPERIMENTAL
Intervention: Run (8.0 km h(‐1))
Number of subjects: 295
Study 16850316 — intervention group
Group type: COMPARATOR
Intervention: Rest
Number of subjects: 295
Study 16850316 — intervention group
Group type: EXPERIMENTAL
Intervention: All conditions
Number of subjects: 295
Study 14634678 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat (120 mg)
Number of subjects: 19
Study 14634678 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 10824049 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg
Number of subjects: 24
Study 10824049 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril 10 mg
Number of subjects: 24
Study 10824049 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 2.5 mg amlodipine and 5 mg lisinopril
Number of subjects: 24
Study 10824049 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine (2.5 mg and 5 mg) and Lisinopril (5 mg and 10 mg)
Number of subjects: 24
Study 8863761 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised (physical therapist‐instructed) group (n = 47)
Number of subjects: 87
Study 8863761 — intervention group
Group type: COMPARATOR
Intervention: Brochure group (n = 40)
Number of subjects: 87
Study 1378112 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine SR (50-100 mg once daily)
Number of subjects: 269
Study 1378112 — intervention group
Group type: COMPARATOR
Intervention: Conventional nifedipine tablet (20-40 mg twice daily)
Number of subjects: 269
Study 1378112 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine SR
Number of subjects: 269
Study 1378112 — intervention group
Group type: COMPARATOR
Intervention: Conventional nifedipine tablet
Number of subjects: 269
Study 7041665 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole 400 mg single dose in adults
Number of subjects: 392